Literature DB >> 7047888

[Fibrinolytic therapy of lower limb deep vein thrombosis with urokinase (author's transl)].

R Zimmermann, J Harenberg, H Mörl, H M Kuhn, P Wahl, P Gerhardt.   

Abstract

In 81 patients with deep vein thrombosis of the lower limb, urokinase therapy was performed in combination with heparin according to a new regimen at higher dosages. When urokinase was administered at an initial maintenance dosage of 1,000-2,000 IU/kg/h (loading dose 150,000-250,000 IU), phlebographically documented complete or partial recanalization could be observed in 68% of the cases. The higher dosage schedule induced a more pronounced deobliteration especially in treatment of iliac vein thromboses (67% recanalization) in comparison to the lower dosage regimen (only 43% recanalization). Nearly comparable therapeutic results could be achieved in therapy of popliteal or saphenous vein thromboses. The data suggest that the higher dosage schedule examined here is indicated in treatment of extensive and large volume thromboses. The dosage of urokinase was further adjusted to attain a reduction of fibrinogen to 50-100 mg/dl. The concentration should not fall below 50 mg/dl. Therapy with urokinase proved practicable. Serious side effects did not occur. 8.6% of the patients showed hematuria and 6% a decrease of the Hb by more than 2 g/dl. The high proportion of older thromboses and the only low rate of recanalization (23%) in these cases suggest the necessity of an early commencement of fibrinolyses in therapy of deep vein thrombosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7047888     DOI: 10.1007/bf01756094

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  29 in total

1.  ASSAY OF UROKINASE PREPARATIONS WITH THE SYNTHETIC SUBSTRATE ACETYL-L-LYSINE METHYL ESTER.

Authors:  S SHERRY; N ALKJAERSIG; A P FLETCHER
Journal:  J Lab Clin Med       Date:  1964-07

2.  Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.

Authors:  I Juhan; M F Calas; M Buonocore; P Mathieu; G Isnard; B Cazenave; A Serradimigni
Journal:  Thromb Haemost       Date:  1979-10-31       Impact factor: 5.249

Review 3.  [Heparin or thrombolysis in the treatment of deep venous thrombosis of the leg].

Authors:  L K Widmer; G Madar; H E Schmitt; F Duckert; M A da Silva; G Müller
Journal:  Vasa       Date:  1974       Impact factor: 1.961

4.  Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. A comparative study between streptokinase and heparin therapy.

Authors:  R Watz; G F Savidge
Journal:  Acta Med Scand       Date:  1979

Review 5.  [Biochemistry of urokinase].

Authors:  F Duckert
Journal:  Folia Haematol Int Mag Klin Morphol Blutforsch       Date:  1971

6.  Blood coagulation changes during effective thrombolysis using urokinase and heparin.

Authors:  G Schöffel; R Zimmermann; J Harenberg; H Mörl
Journal:  Thromb Res       Date:  1982 Jan 1-15       Impact factor: 3.944

7.  Urokinase therapy: dose reduction by administration in plastic material.

Authors:  R Zimmermann; G Schöffel; J Harenberg
Journal:  Thromb Haemost       Date:  1981-06-30       Impact factor: 5.249

8.  [Conservative treatment of deep leg thromboses].

Authors:  V Tilsner
Journal:  Dtsch Med Wochenschr       Date:  1980-01-25       Impact factor: 0.628

9.  [Fibrinolytic treatment with urokinase of post acute phlebothromboses (author's transl)].

Authors:  G Trübestein; T Brecht; F Etzel
Journal:  Dtsch Med Wochenschr       Date:  1979-08-31       Impact factor: 0.628

10.  Streptokinase treatment of deep venous thrombosis and the postthrombotic syndrome. Follow-up evaluation of venous function.

Authors:  U Albrechtsson; J Anderson; E Einarsson; B Eklöf; L Norgren
Journal:  Arch Surg       Date:  1981-01
View more
  1 in total

Review 1.  [Fibrinolytic therapy of deep vein thrombosis].

Authors:  B Weidmann; W Jansen; B Franzen; M Tauchert
Journal:  Med Klin (Munich)       Date:  1999-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.